Key Takeaways:
- West Pharma shares surged 32.9% year to date, outpacing the S&P 500
- Q1 revenue rose 21% to $845 million, with adjusted EPS jumping 47%
- GLP-1 drug demand and biologics growth drove the rally, prompting a guidance raise
Back
West Pharma surges 33% in 2026 as GLP-1 demand fuels growth
West Pharmaceutical Services has rallied nearly 33% year to date, powered by a first-quarter earnings beat and accelerating demand for injectable drug components tied to GLP-1 therapies and biologics.
West Pharmaceutical Services Inc. shares surged 32.9% year to date, outpacing the S&P 500's 28.2% gain, after first-quarter revenue rose 21% to $845 million.
"GLP-1 products now represent 10% of total company sales, with demand supported by broader insurance coverage, reduced drug pricing and new indications," West Pharmaceutical Services management said on the Q1 earnings call.
High-Value Product components, which account for nearly half of revenue, delivered 23% organic growth in the quarter. The biologics business posted 26% organic growth, driven by adoption of NovaPure packaging solutions and global biosimilar launches. Adjusted operating margin expanded 350 basis points to 21.4%.
The strong performance prompted management to raise full-year guidance. The Zacks consensus estimate calls for 2026 earnings per share of $8.60, implying 18% growth, and revenue of $3.33 billion, up 8.4%.
GLP-1 Demand Drives High-Value Product Growth
Accelerating demand for GLP-1 therapies used to treat obesity and diabetes remains West Pharma's largest growth catalyst. Management believes the adoption of oral GLP-1 therapies is expanding the overall market rather than replacing injectable therapies, supporting long-term growth visibility. The company expanded its Dublin manufacturing facility to support high-volume injectable therapies, particularly next-generation GLP-1 treatments.
Annex 1 Regulations Create Multi-Year Tailwind
European Annex 1 sterile manufacturing regulations are creating another growth catalyst. West Pharma reported a 66% year-over-year increase in Annex 1-related projects, with management expecting these initiatives to contribute approximately 200 basis points to 2026 revenue. Pharmaceutical companies are converting standard components toward higher-value HVP solutions to meet stricter compliance requirements, a transition that is also supporting margin expansion.
Competition and Risks Remain
Competition from Baxter International Inc. and Becton Dickinson and Co. remains significant. Baxter reported only 3% sales growth while facing manufacturing cost inflation and tariff pressure, while BD posted 2.6% revenue growth with double-digit expansion across biologic drug delivery platforms. West Pharma's sharper focus on high-value pharmaceutical packaging gives it a concentrated growth advantage in 2026.
Risks include rising oil and commodity costs that could pressure margins, the SmartDose 3.5 divestiture to AbbVie Inc. for $112.5 million removing a prior revenue stream, and dependence on continued injectable GLP-1 demand growth. The Zacks consensus estimate for 2027 earnings per share stands at $9.50, implying 10.5% growth, with revenue projected at $3.54 billion.
The guidance raise signals management expects structural demand from GLP-1 therapies and biologics to sustain momentum. Investors will watch the Q2 earnings report for updated segment margins and any shifts in the competitive landscape.
This article is for informational purposes only and does not constitute investment advice.
© 2026 Edgen Powered by